Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept
Figure 1
A section of human gastroesophageal adenocarcinoma stained by an anti-EGFR monoclonal antibody and biotin streptavidin 3,-diaminobenzidine method (Courtesy of Dr. Amanda Baker, University of Arizona).
